Coya Therapeutics Reports Q3 Revenue of $0.23 Million, Net Loss of $10. ...
Enrollment Completion of Phase 2/3 ALSTARS Trial Anchors a Quarter Marked by Higher R&D Spending and a $35.8 Million Cash Position Related Stocks: COYA ,
Enrollment Completion of Phase 2/3 ALSTARS Trial Anchors a Quarter Marked by Higher R&D Spending and a $35.8 Million Cash Position Related Stocks: COYA ,